Disclaimer: This is a simplified summary of a public company filing. See full disclaimer here.

Earth Science Tech, Inc.

CIK: 15384952 Annual ReportsLatest: 2025-06-27

10-K / June 27, 2025

Revenue:$33,117,624
Income:$3,253,635

10-K / June 28, 2024

Revenue:$11,953,635
Income:$812,139

10-K / June 27, 2025

Summary of Earth Science Tech, Inc.

Business Overview

  • Type of Business: Holding company focusing on acquisitions and management of subsidiaries in healthcare, real estate, and consumer products.

  • Core Operations:

    • Pharmaceutical Compounding: Operates fully licensed compounding pharmacies (RxCompound and Mister Meds) specializing in sterile and non-sterile preparations. RxCompound is licensed in numerous U.S. states and actively expanding licensure.
    • Telemedicine: Platforms (Peaks and DOConsultations) facilitating asynchronous and synchronous healthcare consultations, primarily for compounded medications and wellness services, with plans to expand nationwide through healthcare provider networks.
    • Healthcare Facility: Villas, a healthcare facility targeted at Spanish-speaking communities, offering sexual health treatments and physical performance solutions.
    • Charitable Arm: Earth Science Foundation, Inc. (ESF), a nonprofit providing assistance for prescription costs.
    • Consumer Products: MagneChef, a direct-to-consumer kitchen product brand, currently producing cooking-related products and expanding its offerings using patents and IP.
    • Veterinary Market: Recently expanded into the veterinary segment through acquisition of Zoolzy.com.
  • Additional Acquisitions & Subsidiaries:

    • Acquired 100% of Las Villas Health Care, Inc. and DOConsultations, LLC.
    • Acquired 80% of MagneChef.
    • Acquired Mister Meds operating in Abilene, Texas with advanced sterile compounding infrastructure (fully licensed in March 2025).
    • Expanded into the veterinary market via Zoolzy.com.

Employees & Customers

  • Employees: 76 as of March 31, 2025.
  • Customers: The company has at least three significant customers who account for approximately 7%, 10%, and 9% of revenue.
  • Beneficial Holders: 209 stockholders as of June 11, 2025.

Revenue & Income

  • Fiscal Year Ended March 31, 2025:
    • Revenue: $33,117,624
    • Gross Profit: $24,300,136 (Gross margin of 73%)
    • Net Income: Approximately $3,272,000
  • Fiscal Year Ended March 31, 2024:
    • Revenue: $11,953,635
    • Gross Profit: $7,828,496 (Gross margin of 65%)
    • Net Income: Approximately $812,000

Financial Highlights

  • The increase in revenue from 2024 to 2025 is primarily due to higher demand for compounded medications.
  • The gross margin improved, driven by better buying power and price negotiations.
  • Operating expenses increased significantly, especially salaries and marketing, reflecting company growth.
  • The company repurchased approximately 14.6 million shares during FY 2025 for around $1.47 million, with some shares canceled and others held in treasury.
  • Cash and cash equivalents totaled approximately $1.47 million as of March 31, 2025, up from roughly $698,000 in 2024.

This summary reflects the company's scope, operational focus, recent acquisitions, financial performance, and workforce without hypothetical or external assumptions.